Transforming vaccines with breakthrough VLP technology

Corporate profile

Icosavax is a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s lead program is a combination vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), and its pipeline includes additional programs in influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases.

Press releases

December 12, 2023
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
December 12, 2023
Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
November 14, 2023
Icosavax Reports Third Quarter 2023 Financial Results and Provides Corporate Update


November 15, 2023 at 11:00 AM EST
Jefferies London Healthcare Conference
November 7, 2023 at 10:30 AM EST
Guggenheim 5th Annual Inflammation, Neurology, & Immunology Conference
September 26, 2023
Cantor Fitzgerald Global Healthcare Conference 2023

Latest presentation

October 2023
Icosavax October 2023 Corporate Presentation
Investor Email Alerts